Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	2.14B -46.7%
Revenue (ttm)	673.00M +20.2%
Net Income	-575.00M
EPS	-5.83
Shares Out	96.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,439
Open	22.40
Previous Close	23.02
Day's Range	22.40 - 22.88
52-Week Range	18.41 - 43.22
Beta	0.16
Analysts	Strong Buy
Price Target	66.32 (+198.34%)
Earnings Date	Feb 12, 2026

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,371
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE
• Website: https://www.ultragenyx.com

Financial Performance

In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.

Analyst Summary

According to 19 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $66.32, which is an increase of 198.34% from the latest price.

Price Target

$66.32

(198.34% upside)

Analyst Consensus: Strong Buy